P atients with established coronary artery disease (CAD) are generally at higher risk of developing recurrent cardiovascular events than individuals without a history of cardiovascular disease (CVD). Compared with primary prevention, the prognostic value of traditional metabolic biomarkers, including serum lipids, in patients with stable CAD is limited. 1 Although traditional risk factors are widely used to predict cardiovascular risk, the specific mechanisms for the development of CVD in secondary prevention remain unclear. As a result, different novel biomarkers that signify subclinical myocardial injury, stress, and inflammation, such as high-sensitivity cardiac troponins and high sensitivity C-reactive protein, and growth-differentiation factor-15 have been explored but provide only modest incremental prognostic information to risk factor models in patients with stable CAD. 1, 2 Metabolic syndrome, including obesity, insulin resistance, hypertension, and hypertriglyceridemia, are important risk factors for the incidence and mortality of CVD. 3 Cardiometabolic biomarkers have been extensively studied in the development of metabolic diseases and have been shown to be closely associated with obesity and related CVD, suggesting that these biomarkers play a potential role in atherosclerotic vascular disease and CAD pathogenesis. 4 Currently, the prognosis of patients with stable CAD based on a panel of cardiometabolic biomarkers for occurrence of cardiovascular events has not been studied.
Adipose tissue is a primary site for energy storage and serves as a major endocrine organ that secretes adipokines, such as adiponectin, A-FABP (adipocyte fatty acid-binding protein), lipocalin-2, plasminogen activator inhibitor-1, and retinol-binding protein-4. [5] [6] [7] The link between adipose tissue and cardiometabolic risk has been found through different pathophysiologic mechanisms, indicating that both fat accumulation and dysfunctional adipose tissue in obesity may contribute to the development of cardiometabolic risk factors, including insulin resistance, dyslipidemia, hypertension, and an inflammatory state that favor atherogenesis. 8 More recently, FGF (fibroblast growth factor)-19 and 21 have also been found to have important metabolic effects in the regulation of energy metabolism and are considered potential therapeutic targets when treating metabolic conditions. 9 In this study, we evaluated the predictive values of these novel cardiometabolic biomarkers and investigated whether these biomarkers, alone or in combination, provide incremental accuracy to predict the risk of major adverse cardiovascular events (MACE) beyond clinical risk factors in 2 independent cohorts of patients with stable CAD.
Materials and Methods
The authors declare that all supporting data are available within the article (and its online-only Data Supplement).
Study Population
Our study discovery cohort consisted of 1166 Chinese with a diagnosis of stable CAD who received evidence-based medical therapies, including coronary revascularization and statins. In this study, consecutive patients admitted into Queen Mary Hospital, Hong Kong, for treatment of stable CAD were recruited between December 2003 and December 2014. Diagnosis of stable CAD was defined according to the American College of Cardiology guidelines. 10 Multiple imputations were used to impute all missing values in anthropometric variables. We implemented this in the R package MICE (multivariate imputation by chained equations).
11 Twenty-four subjects with missing biomarker measurements were excluded.
An additional validation cohort which consisted of 1262 patients with stable CAD recruited from the Hong Kong West Diabetes Registry cohort and comprising type 2 diabetes mellitus (T2DM) patients who regularly attended the Diabetes Clinic at the Queen Mary Hospital. They were enrolled consecutively between 2008 and 2013 to participate in a prospective study to identify the risk factors predisposing to the development of diabetic complications. Study design and inclusion criteria have been described previously. 12 This study was approved by the local Institutional Review Board, and written informed consent was obtained from each patient.
Baseline Examinations
All enrolled patients were required to complete a standardized questionnaire to collect comprehensive data on medical and family history, medication use, smoking status, and anthropometric measurements, including body weight, height, and systolic and diastolic blood pressure. Patients were defined as current smoker if they reported any tobacco use in the last 30 days. 13 Blood pressure was measured in the right arm with the patient rested for 10 minutes. Hypertension referred to the presence of a hypertension history or regular prescription of antihypertensive medications. T2DM was defined according to the World Health Organization 1998 diagnostic criteria or if the patient was prescribed regular antidiabetic medications. 14 
Laboratory Measurements
To improve the conventional method of risk prediction, a panel of biomarkers associated with cardiometabolic diseases, including serum adiponectin, A-FABP, lipocalin-2, FGF-19, FGF-21, plasminogen activator inhibitor-1, and retinol-binding protein-4 were chosen based on the prior studies that have shown substantial predictive values in the development of CVD or causal associations in animals. [15] [16] [17] [18] [19] [20] [21] All patients in the discovery cohort had valid measurements of 7 biomarkers on admission for the index event. Selected biomarkers based on the results from the discovery cohort were measured in the validation cohort. Blood samples were drawn from all patients on recruitment after an overnight fast and stored at −70°C for measurement of biomarkers, fasting lipid, and glucose. The serum levels of each biomarker were determined using ELISA kits that were established in our laboratories (Antibody and Immunoassay Services, The University of Hong Kong) as previously reported. 16, 17, 22, 23 As the measurement of all biomarkers were not standardized and there was no standardized actual value, no measurement bias could be determined. The intra-assay and interassay coefficients of variations for adiponectin, A-FABP, lipocalin-2, FGF-19, FGF-21, plasminogen activator inhibitor-1, and retinol-binding protein-4 were 4.0% and 9.5%, 3.8% and 5.7%, 3.1% and 9.0%, 4.5% and 5.6%, 1.7% and 2.6%, 3.6% and 4.4%, 1.8% and 2.4%, respectively. The lowest detection limit and assay range were 1.56 ng/mL (1.56-100), 0. 
Outcomes and Follow-Up
Patient follow-up began at enrollment and continued until the diagnosis of a cardiovascular end-point, death, last visit, or December 31, 2015, whichever came first. The cardiovascular end points of this study were new-onset MACE during the follow-up period. We adjudicated newonset MACE based on the International Classification of Diseases, Ninth Revision (ICD-9), consisting of acute myocardial infarction (ICD-9 410), acute coronary syndrome (ICD-9 411.1), stroke (ICD-9 430, 431, 433, 434, 436), peripheral vascular disease (ICD-9 443.9), and cardiovascular death (death certificate ICD-9 410-447). Information on discharge diagnosis and date of events were confirmed by review of medical records from the electronic database of the Hong Kong Hospital Authority. For patients who died during follow-up, the main cause and date of death were obtained from the Hong Kong Death Registry.
Statistical Analysis
Data are expressed as mean±SD for continuous variables and number and percentage for categorical variables. The Kolmogorov-Smirnov test was used to evaluate the normality assumption for continuous variables. Skewed variables, such as the biomarkers, were logarithmically transformed to achieve a normal distribution before analysis. Subjects were divided into 2 age groups, <65 years and 65+ years. Comparisons between groups were evaluated by Student t test or χ 2 test as indicated. Pearson correlation coefficients were obtained between biomarkers and clinical risk factors at baseline. Youden J index was used to determine the optimal cutoff value for each biomarker. 24 Hosmer-Lemeshow goodnessof-fit was used to test the calibration. Based on the findings from a previous study, 15 assuming the new prediction model with multiple biomarkers and clinical risk factor to detect a hazard ratio (HR) of 1.57 for MACE, 155 events were required to provide an 80% power with a 2-sided significance level of 0.05. Effective sample size for discovery and validation cohort was achieved by using the 10 events per variable rules for Cox regression-based prediction models. 25 Cox proportional hazards regression was performed to investigate the associations of age, biomarkers, and clinical risk factors with MACE. We used hypertension and T2DM in model selection rather than diastolic blood pressure and hemoglobin A1c to ensure sufficiency when examining the association with MACE because many factors, such as antihypertensive and antidiabetic medications, could cause variations in these quantitative parameters. We examined the variables that associated with cardiovascular outcomes and used 3 steps to evaluate the models in Cox proportional hazards analyses.
Step 1: age ≥65 years; step 2: age ≥65 years and clinical risk factors; and step 3: additional inclusion of the biomarkers (categorized by the optimal cutoff values), alone, or in combination. The multivariable Cox regression model was built using forward selection that minimizes the Akaike information criterion. 26 The relationship between baseline level of biomarkers (high versus low cutoff values) and MACE was assessed using Kaplan-Meier survival curve and log-rank test.
A 2-sided P value <0.05 was considered statistically significant. The statistical software packages SPSS (version 19; SPSS, Chicago, IL), STATA (version 14.0), and R-programming language (version 3.4.3) were used.
Results

Clinical Outcomes
In this study, 875 (75%) CAD patients in the discovery cohort had undergone coronary revascularization, and all were prescribed antiplatelet therapy and a statin at baseline. After a median follow-up of 35 months, 170 (incidence rate, 3.4 per 100 patient-year) patients developed new-onset MACE. Among them, 31 (18%) developed a nonfatal acute myocardial infarction, 27 (16%) had a nonfatal acute coronary syndrome, 25 (15%) had a nonfatal stroke, 10 (6%) had symptomatic peripheral vascular disease requiring treatment, and 77 (45%) died from cardiovascular causes. Table 1 summarizes the demographic and biochemical characteristics of CAD patients in the discovery cohort with or without MACE during follow-up. At baseline, individuals with an incident of MACE were significantly older, had a higher proportion of hypertension and T2DM, and lower diastolic blood pressure than those who did not develop a MACE (all P<0.001). In addition, the serum levels of adiponectin, A-FABP, lipocalin-2, FGF-19, and FGF-21 were significantly higher (all P<0.05) in patients with a MACE than those without. Nonetheless, there were no significant differences in body mass index, plasminogen activator inhibitor-1, and retinol-binding protein-4 between patients with or without a MACE (all P>0.05).
Relationships Between Different Biomarkers
The Pearson correlation coefficients between those biomarkers with significant differences between patients with or without a MACE and clinical risk factors are presented in Table I in the online-only Data Supplement. Serum A-FABP, lipocalin-2, and FGF-21 levels were positively correlated with hypertension, whereas positive correlation with T2DM was only found in A-FABP (all P<0.01). There were inconsistent correlations between body mass index and different biomarkers. Interestingly, all biomarkers were positively correlated with each other, except for adiponectin and FGF-21. A moderately strong correlation was observed between A-FABP and lipocalin-2 (r=0.48; P<0.01), whereas a weaker correlation was noted between A-FABP and FGF-19 (r=0.16; P<0.01).
Predictive Values of Biomarkers
The optimal cutoff levels of individual biomarkers in predicting MACE were 2.52, 3.41, 4.59, 4.98, and 5.88 for adiponectin, A-FABP, lipocalin-2, FGF-19, and FGF-21, respectively. A forest plot of unadjusted HR for the risk of MACE is shown in Figure I in the online-only Data Supplement. There was no significant association between body mass index with MACE in the univariate analysis, and body mass index remained insignificant in the age and clinical risk factors adjusted model (HR, 0.96, 95% CI, 0.92-1.01; P=0.13). In this study, sex differences in adiponectin levels were observed in which the levels were significantly lower in men than in women (logtransformed adiponectin levels: 2.4±0.6 versus 2.8±0.6; P<0.001). However, after the additional adjustment of male sex in the multivariable model, only a relatively small change in HR was observed for high adiponectin levels (HR, 1.77 versus 1.72, model adjusted for age ≥65, hypertension, and T2DM). As a result, only age ≥65 years, T2DM and hypertension were selected in the final model. In the multivariable Cox regression analyses, the model with the lowest Akaike information criterion was obtained using stepwise forward selection method to identify the optimal numbers and combination of biomarkers for the age-biomarkers-clinical [ABC] risk factor approach ( Table 2 ). The model with age ≥65 years alone yielded an AUC of 0.61 (P<0.001). The addition of T2DM and hypertension significantly increased the AUC to 0.68 (P<0.001). In the single biomarker approach, the best predictor value was found for the addition of high lipocalin-2 levels to the ageclinical risk factor model, with AUC increased to 0.73 (difference in AUCs, 0.05; P<0.001). The AUC further increased to 0.75 when a combination of high cutoff levels of lipocalin-2, A-FABP, and FGF-19 was incorporated into the model with age ≥65 years, T2DM and hypertension, incremental benefit was found in comparison to single biomarker model (difference in AUCs, 0.02; P=0.038). In addition, net reclassification improvement (21.8%; P<0.001) and integrated discrimination improvement (7.4%; P<0.001) were significant in the final model, indicating the improvement in the predictive performance of the multibiomarker ABC model.
Kaplan-Meier event-free survival curves for a MACE are shown in Figure 1 . The annual event rate of MACE in CAD patients ≥65 years with T2DM and hypertension was 5.7 per 100 patient-years but significantly increased to 14 per 100 patient-years if serum levels of lipocalin-2, A-FABP, and FGF-19 were above the cutoff values. The event-free survival was significantly lower in elderly patients with both T2DM and hypertension compared with young patients without T2DM or hypertension (log-rank test, P<0.001). Moreover, CAD patients with lipocalin-2, A-FABP, and FGF-19 levels above the cutoff values had significantly worse adjusted event-free survival than those with levels below the cutoff values (logrank test, P<0.001).
Multivariable Cox regression analysis was also used to determine the independent predictors of a MACE. As shown in 
Validation of ABC Risk Factor Approach in Diabetic Patients With CAD
In the validation cohort of T2DM patients with CAD, A-FABP, FGF-19, and lipocalin-2 were measured using ELISA with quality control performed as the discovery cohort. The demographic and biochemical characteristics of the validation cohort are presented in Table 4 . Compared with the discovery cohort, the validation cohort had significantly higher proportion of elderly, hypertension, and nonsmoker (P<0.01). Moreover, the A-FABP level was significantly lower, and the lipocalin-2 level was higher in the validation cohort than the discovery cohort (Table II in the online-only Data Supplement). During the follow-up period, there were 251 T2DM patients who experienced MACEs which was significantly higher than the proportion in the validation cohort (20% versus 15%; P<0.001).
Optimal cutoff level of biomarkers derived from the discovery cohort was used. The model with age ≥65 years and hypertension yielded an AUC of 0.58 (P<0.001). Incorporating a combination of lipocalin-2 and A-FABP at high levels into the model with age ≥65 years and hypertension increased the AUC to 0.62 (difference in AUCs versus age and risk factors model, 0.04; P<0.001). The AUC further increased to 0.63 when high FGF-19 levels were added into the ABC model with a combination of A-FABP and lipocalin-2, providing significant incremental value in comparison to single biomarker model (difference in AUCs, 0.03; P=0.005; Table 5 ). The ABC models indicated good discrimination and calibration in single and multibiomarker approach (Hosmer-Lemeshow goodness-of-fit, P>0.5). Kaplan-Meier event-free survival curves for a MACE in the validation cohort are shown in Figure 2 . Similar to the discovery cohort, the event-free survival was significantly lower in elderly patients with both T2DM and hypertension compared with young patients without T2DM or hypertension (log-rank test, P<0.001). Furthermore, CAD patients with lipocalin-2, A-FABP, and FGF-19 levels above the cutoff values had significantly worse adjusted event-free survival than those with levels below the cutoff values (log-rank test, P<0.001).
Discussion
In the present study of patients with stable CAD, clinical risk factors included age and the presence of hypertension and T2DM, in addition to elevated serum levels of 5 cardiometabolic biomarkers, adiponectin, A-FABP, lipocalin-2, FGF-19, and FGF-21, were independently associated with increased risk of developing cardiovascular events. Similar to previous reports, [27] [28] [29] our results confirm that age, hypertension, and T2DM are the common predictors of MACE in CAD patients. This study demonstrates that a panel of cardiometabolic biomarkers was independently associated with new-onset MACE in patients with stable CAD. Moreover, the approach of incorporating these cardiometabolic biomarkers into the model with age and clinical risk factors, that is, ABC risk factors approach, can further improve the risk prediction of incident MACE in patients with stable CAD. Using a stepwise selection approach, we demonstrated that 3 of these 5 cardiometabolic biomarkers could enhance the predictive values beyond the clinical risk factors for MACE in stable CAD. This multibiomarker approach comprising A-FABP, lipocalin-2, and FGF-19 was found to significantly improve cardiovascular risk prediction beyond clinical risk factors, as evidenced by the AUC increasing from 0.68 to 0.75, and was shown to have a significantly better performance than the single biomarker approach. Nonetheless, adiponectin and FGF-21 did not provide any incremental predictive values. Indeed, multivariable analysis confirmed that advanced age, T2DM, and hypertension, as well as serum levels above cutoff for A-FABP, lipocalin-2, and FGF-19 emerged as independent predictors of MACE in patients with stable CAD. Kaplan-Meier curves also showed that elderly patients with clinical risk factors and levels of biomarkers above cutoff were associated with increased MACE. We further validated the predictive performance of this ABC risk model in another cohort of CAD patients with T2DM. Our results showed our ABC risk factor approach using multiple biomarkers have good discrimination and calibration in a cohort of T2DM patients with stable CAD.
Previous studies have explored the predictive value of adiponectin, lipocalin-2, A-FABP, and FGF-19 and FGF-21 for CVD in high-risk subjects with CAD or T2DM. Prior analysis revealed conflicting findings with negative, positive, or no relationships between adiponectin level and CVD risk. 20 In the Women's Health Initiative Observational Study, 20 female patients with T2DM and elevated plasma levels were associated with increased risk of MACE. Schnabel et al 30 also reported the association between adiponectin and adverse cardiovascular outcome in patients with manifest CAD. Indeed, we observed elevated adiponectin levels in CAD patients with MACE than those without. In contrast to patients without CAD, hyperadiponectinemia may represent an anti-inflammatory response to disease presence and severity of atherosclerosis in patients CAD. 20 Similarly, in patients with acute myocardial infarction who underwent primary percutaneous coronary intervention, an elevated lipocalin-2 level predicted all-cause mortality and MACE during follow-up. 31 In a long-term prospective study, von Eynatten et al 32 showed that increased serum level of A-FABP was associated with increased risk of future CVD events. Recently, Li et al 18 reported that both higher and lower serum levels of FGF-21 were associated with increased CVD mortality. Our previous studies also demonstrated that elevated A-FABP 33 and FGF-21 34 were associated with increased MACE in patients with T2DM. The results of this study further confirm the associations of these individual cardiometabolic biomarkers with subsequent risk of CVD events and cardiovascular mortality in patients with stable CAD with or without T2DM. Moreover, we performed a direct head-to-head comparison of these biomarkers for prediction of MACE in stable CAD patients. Among them, an elevated A-FABP level provided the best AUC for predicting a MACE, but an increased lipocalin-2 level was associated with a higher HR for MACE in stable CAD patients. However, when combined with clinical risk factors, an increased lipocalin-2 level was associated with the best AUC in stable CAD patients for a single biomarker approach. Nevertheless, to the best of our knowledge, there are no published data on the potential incremental role of different combinations of cardiometabolic biomarkers for CVD event prediction. In this study, only the combination of A-FABP with FGF-19, not either of them alone, significantly improved the predictive value of lipocalin-2 for MACE, on top of the clinical risk factors. We further confirmed this multiple cardiometabolic biomarkers approach in patients with CAD and T2DM. In CAD patients with T2DM, lipocalin-2, FGF-19, and A-FABP alone provided similar increase predictive value, and the combination of all 3 biomarkers provided the best AUC for predicting a MACE on top of the clinical risk factors.
Few studies have investigated the association of multiple cardiometabolic biomarkers with CVD risk. Novotny et al 35 reported that circulating A-FABP, adiponectin, and FGF-21 were significantly correlated with each other in patients with metabolic syndrome. In contrast, our prior community-based prospective study showed that serum A-FABP was negatively correlated with adiponectin and positively correlated with Values are mean±SD or n (%). A-FABP indicates adipocyte fatty acidbinding protein; BMI, body mass index; FGF, fibroblast growth factors; HbA1c, hemoglobin A1c; HDL-C, high-density lipoprotein cholesterol; LDL-C, lowdensity lipoprotein cholesterol; Ln, natural logarithm; and MACE, major adverse cardiovascular events. high-sensitivity C-reactive protein. 15 Similarly, in collaboration with colleagues in Shanghai, we also demonstrated that serum level of lipocalin-2 was negatively correlated with adiponectin and positively correlated with high-sensitivity C-reactive protein. 16 In the current study, serum A-FABP, lipocalin-2, and FGF-19 levels were positively associated with other cardiometabolic biomarkers (adiponectin, A-FABP, lipocalin-2, FGF-19, and FGF-21). Nonetheless, there was no relationship between serum levels of adiponectin and FGF-21 in our patients with stable CAD. Moreover, serum levels of A-FABP and lipocalin-2 were positively correlated with age, hypertension, and serum triglyceride level and negatively with male sex, diastolic blood pressure, and serum HDL-C (high-density lipoprotein cholesterol) level, consistent with our previous studies. 16 The independent relationship and synergic predictive role of A-FABP and lipocalin-2 to subsequent risk of CVD may be explained by the fact that they are both key proinflammatory mediators linked to cardiovascular and metabolic abnormalities that are involved in the pathogenesis of atherosclerotic plaque. 36, 37 In this study, our results confirmed these observations and provided novel evidence that elevated FGF-19 level was associated with increased risk of a MACE in stable CAD patients with or without T2DM. Similar to FGF-21, FGF-19 is a member of the endocrine FGF family. It is secreted from the ileum during feeding and is involved in the regulation of hepatic bile acid synthesis, lipid, and glucose metabolism. 38 There are currently limited data on the relationship between serum level of FGF-19 and CVD. In a diabetic population, the alteration in serum FGF-19 level is controversial. Compared with controls, some studies showed that circulating level of FGF-19 was decreased in patients with impaired fasting glucose and diabetes mellitus, 17 whereas others suggested no difference 39, 40 or an even higher 41 fasting serum FGF-19 level in diabetic patients. Hao et al 42 reported decreased circulating FGF-19 in 228 CAD patients, and the serum level was negatively associated with the presence and severity of coronary lesions. There are no data on the prognostic role of serum FGF-19 level in patients with CAD. In this study, we included a much larger number of stable CAD patients who had been prescribed evidence-based medical therapies, including statin therapy and demonstrated that an elevated serum FGF-19 level was associated with an increased risk of MACE on longterm follow-up. In our cohort of CAD patients with T2DM, there was no difference in the FGF-19 level between patients with or without MACE, but an elevated FGF-19 still provide incremental predictive value in combination with A-FABP and lipocalin-2. It is possible that the occurrence of a reduced hepatic response to circulating FGF-19 in CAD patients, as reported in patients with insulin resistance, 43 might have resulted in the compensatory increase in serum FGF-19 and was associated with increased risk of CVD events and mortality. In this study, the addition of serum level of FGF-19 to A-FABP and lipocalin-2 provided further incremental predictive value in our cohort of CAD patients with or without T2DM. This finding further supports our hypothesis that the inclusion of multiple biomarkers provides better risk discrimination for CVD events beyond clinical risk factors. Further studies are needed to confirm our findings on the prognostic role of serum level of FGF-19 in patients with CVD.
The results of this study have potential important clinical implications. Although the overall annual CVD event rate in our cohort of CAD patients was low, those with clinical risk factors (age ≥65 years, T2DM and hypertension) and elevated serum levels of cardiometabolic biomarkers (A-FABP, lipocalin-2, and FGF-19) had an annual event rate of 14%, suggestive of significant residual risk despite being prescribed evidence-based medical therapies. Indeed, our average LDL-C (low-density lipoprotein cholesterol) level (2.2 mmol/L) and annual CVD events rate (3.4%) in this study are comparable with those of recent clinical trials in patients with stable CAD. 44, 45 This ABC risk factor approach may allow us to identify patients at high risk of incident CVD who should be subjected to more aggressive risk factor control and close surveillance. Whether the ABC risk factor approach proposed in this study can be used to select high-risk stable CAD patients for targeted intensive lipid-lowering therapies, such as proprotein convertase subtilisin-kexin type 9 inhibition, 44 or novel anti-inflammatory agents, such as monoclonal antibody targeting interleukin-1β, 45 deserves further investigation. Our results extend the findings from previous studies showing the potential role of A-FABP, lipocalin-2, and FGF-19 as important pathophysiological mediators of CVD and the possibility of identifying new treatment targets for the prevention of recurrent cardiovascular events in patients with established CAD.
This study has its limitations. Although it was based on a prospective design, it remains unclear if these biomarkers play a causal role in the development of recurrent cardiovascular events. We did not measure other biomarkers, such as high-sensitivity C-reactive protein, growth-differentiation factor-15, or B-type natriuretic peptide that might have further strengthened the predictive value for cardiovascular events. 15, 46 In the validation cohort, all CAD patients experienced T2DM, and their demographic features, such as LDL-C and hemoglobin A1c levels, and their annual CVD events rate (4.5%) were different from the discovery cohort. As a result, the magnitude of the incremental value of the combined cardiometabolic biomarkers is smaller than the discovery cohort. Nonetheless, our findings confirmed that the ABC risk factor approach can be used in stable CAD patients with or without T2DM to identify high-risk patients for recurrent CVD events.
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